Photo of Bexis

We just noticed this piece in Bloomberg News (via Pharmalot) about a hearing before Judge Weinstein on Thursday, April 10, in the consolidated Zyprexa cases.
Presumably keenly aware of the Second Circuit’s recent reversal of his decision to certify a consumer fraud class in the tobacco litigation (about which we posted here), Judge Weinstein suggested that he probably will not certify a similar class of purchasers of Zyprexa.
That decision is not surprising. Trial court judges are, of course, supposed to learn from and follow circuit precedent.
But the “comments” over at Pharmalot are more surprising. Readers are accusing Judge Weinstein of “hypocrisy” and being on “Lilly’s take” because of what he said at the hearing.
Lord knows that we, too, are occasionally a bit shrill, but we try not to criticize folks who are simply trying to do their jobs conscientiously and in good faith.